Stockwatch: Big pharma looks on while Amgen splurges
This article was originally published in Scrip
Executive Summary
It’s been a number of years since the pharmaceutical sector was held in the same esteem by investors for industries that are defensive and counter-cyclical; sectors whose sales and earnings growth continue even in a recession and, like tobacco and gambling, may increase in spite of it. The pharmaceutical industry used to have no natural predators, except itself and time.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.